Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03121534 · ClinicalTrials.gov registry record · Phase 2
Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT03121534: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT03121534 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03121534, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if blinatumomab can help to control Richter Transformation (RT, a type of blood cancer). The safety of this drug will also be studied. This is an investigational study. Blinatumomab is FDA approved and commercially available for the treatment of acute lymphoblastic leukemia (ALL). It is investigational to use blinatumomab to treat patients with RT. The study doctor can explain how the study drug is designed to work. Up to 21 participants will be enrolled in this study. All will take part at MD Anderson.
Interventions
- DRUG Nivolumab
- DRUG Dexamethasone
- DRUG Blinatumomab
- DRUG Ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-06-22 |
| Est. Completion | 2022-02-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03121534
The ClinicalTrials.gov registry entry for NCT03121534 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nivolumab is the first listed.
NCT03121534 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03121534 about?
NCT03121534 is a clinical study titled "Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation". The goal of this clinical research study is to learn if blinatumomab can help to control Richter Transformation (RT, a type of blood cancer). The safety of this drug will also be studied. This is an investigational study. Blinatumomab is FDA approved and commercially available for the treatment of ...
What is the current status of trial NCT03121534?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2017-06-22. Estimated completion is 2022-02-11.
What interventions are being tested in trial NCT03121534?
The interventions under investigation include: Nivolumab (DRUG), Dexamethasone (DRUG), Blinatumomab (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT03121534?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.